^
    1d
    Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Suspended, University of Utah | Recruiting --> Suspended
    Trial suspension
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Tazverik (tazemetostat)
    4d
    Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. (PubMed, Clin Lymphoma Myeloma Leuk)
    Noncovalent BTK inhibitors, particularly pirtobrutinib, has shown impressive activity in patients who have progressed on covalent BTKi. The FDA approval of lisocabtagene maraleucel represents a significant milestone in the treatment of double refractory CLL, providing a potentially curative option for eligible patients. The development of effective treatments for double refractory CLL represents an urgent unmet clinical need and the promising results from emerging therapies offer hope for improved outcomes in this challenging patient population.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Breyanzi (lisocabtagene maraleucel) • Jaypirca (pirtobrutinib)
    4d
    A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease (clinicaltrials.gov)
    P2, N=30, Recruiting, Sanofi
    Trial initiation date
    6d
    ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, KeshuZhou
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • lenalidomide • Brukinsa (zanubrutinib)
    6d
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P3, N=240, Recruiting, Hutchmed | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • HMPL-760
    6d
    Intermittent ibrutinib in chronic lymphocytic leukemia (2023-508638-32-00)
    P1, N=50, Active, not recruiting, Karolinska University Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imbruvica (ibrutinib)
    6d
    CLLRT2: A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation (2024-513445-37-00)
    P2/3, N=57, Not yet recruiting, University Of Cologne
    New P2/3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    7d
    CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer. (PubMed, Cell Death Dis)
    By drug screening, Ibrutinib is identified as an effective inhibitor of HGSOC cells and patient-derived organoids with CBX2 condensates. Overall, CBX2 phase separation enhances DSB repair-mediated drug resistance in HGSOC cells, and Ibrutinib may offer a viable therapeutic option for CBX2-positive HGSOC patients.
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • CBX2 (Chromobox 2)
    |
    Imbruvica (ibrutinib)
    7d
    IgG-κ lymphoplasmacytic lymphoma complicated by bilateral femoral neck fractures secondary to bone involvement (PubMed, Rinsho Ketsueki)
    Ibrutinib plus rituximab therapy was administered, resulting in a partial response sustained to date. Bone involvement and amyloidosis are rare but critical extranodal manifestations of LPL, necessitating careful screening and follow-up even in asymptomatic patients. When these manifestations are suspected, prompt pathological and genetic evaluation is warranted, especially in non-IgM LPL cases.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab)
    7d
    A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=3, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting --> Completed | N=356 --> 3 | Trial completion date: Dec 2027 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Inokai (orelabrutinib)
    8d
    Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) (clinicaltrials.gov)
    P2, N=119, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial primary completion date: Mar 2027 --> Jan 2026
    Trial primary completion date
    |
    temozolomide • Velexbru (tirabrutinib)
    8d
    Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation (clinicaltrials.gov)
    P2, N=35, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    cyclophosphamide • Inokai (orelabrutinib) • Polivy (polatuzumab vedotin-piiq)